4-epidoxorubicin in recurrent cervical cancer - PubMed (original) (raw)
4-epidoxorubicin in recurrent cervical cancer
L C Wong et al. Cancer. 1989.
Abstract
Thirty-eight patients with histologically proven recurrent cervical cancer were treated with epirubicin, an analogue of anthracycline. There were eight complete responders and ten partial responders. The overall response rate was 47.8%. The survival duration of the responders was significantly longer than that of the nonresponders. The optimal dose of epirubicin has yet to be determined. The dosage of 120 mg/m2 was well tolerated. The role of epirubicin as an adjuvant chemotherapeutic agent in the treatment of cervical cancer was discussed.
Similar articles
- Single agent epirubicin in squamous cell cervical cancer. A phase II trial.
Calero F, Rodriguez-Escudero F, Jimeno J, Mendaña J, Iglesias J, Murillo F, Ugalde F, Armas A, Rementeria A, Asins J, et al. Calero F, et al. Acta Oncol. 1991;30(3):325-7. doi: 10.3109/02841869109092379. Acta Oncol. 1991. PMID: 2036241 Clinical Trial. - Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
Zanetta G, Fei F, Mangioni C. Zanetta G, et al. Semin Oncol. 2000 Feb;27(1 Suppl 1):23-7. Semin Oncol. 2000. PMID: 10697040 Review. - Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study.
van der Burg ME, Monfardini S, Guastalla JP, de Oliveira C, Renard J, Vermorken JB. van der Burg ME, et al. Eur J Cancer. 1992;29A(1):147-8. doi: 10.1016/0959-8049(93)90596-8. Eur J Cancer. 1992. PMID: 1280152 Clinical Trial. - Epirubicin: a phase II study in recurrent small-cell lung cancer.
Rosenthal M, Kefford R, Raghavan D, Stuart-Harris R. Rosenthal M, et al. Cancer Chemother Pharmacol. 1991;28(3):220-2. doi: 10.1007/BF00685514. Cancer Chemother Pharmacol. 1991. PMID: 1713130 - Bevacizumab for the treatment of cervical cancer.
Bizzarri N, Ghirardi V, Alessandri F, Venturini PL, Valenzano Menada M, Rundle S, Leone Roberti Maggiore U, Ferrero S. Bizzarri N, et al. Expert Opin Biol Ther. 2016;16(3):407-19. doi: 10.1517/14712598.2016.1145208. Expert Opin Biol Ther. 2016. PMID: 26796332 Review.
Cited by
- Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A, Cetina L, Coronel J, Martínez-Baños D. Dueñas-González A, et al. Drugs. 2010 Mar 5;70(4):403-32. doi: 10.2165/11534370-000000000-00000. Drugs. 2010. PMID: 20205484 Review. - Radiosensitizers in cervical cancer. Cisplatin and beyond.
Candelaria M, Garcia-Arias A, Cetina L, Dueñas-Gonzalez A. Candelaria M, et al. Radiat Oncol. 2006 May 8;1:15. doi: 10.1186/1748-717X-1-15. Radiat Oncol. 2006. PMID: 16722549 Free PMC article. - Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Plosker GL, Faulds D. Plosker GL, et al. Drugs. 1993 May;45(5):788-856. doi: 10.2165/00003495-199345050-00011. Drugs. 1993. PMID: 7686469 Review.